Ultralow-dose 4 Gy RT for myeloma bone metastases
ForMultiple myeloma, uncomplicated painful bone lesion; 79% prior chemo
TL;DRPain response 59% at 4 wks (per protocol; ITT 40/70, 57%) after 4Gy to painful MM bone lesions; 24% needed a second RT course.
The ITT read runs opposite to the abstract's framing: CR+PR was 40/70 (57%) at 4 wks, 33/70 (47%) at 8 wks and 37/70 (53%) at 6 mo, with 25/70 (36%) not completing the 6 mo assessment. The decision in play is 4Gy first with reRT held in reserve; 24% needed a second course.
In MM with an uncomplicated painful bone lesion, this supports 4Gy as a response-adapted first step with reirradiation in reserve; it does not extend to complicated lesions or to pts who need fast relief, given a median 36 days to pain relief.
The ITT read runs opposite to the abstract's framing: CR+PR was 40/70 (57%) at 4 wks, 33/70 (47%) at 8 wks and 37/70 (53%) at 6 mo, with 25/70 (36%) not completing the 6 mo assessment. The decision in play is 4Gy first with reRT held in reserve; 24% needed a second course.
12 details
Prospective, multi-institutional, single-arm phase II. 63 evaluable pts with 70 lesions from 7 institutions, treated 4/2019-9/2025. Median follow-up after RT 186 days.
Multiple myeloma with an uncomplicated painful bone lesion. Median age 66, 49% female, 89% ECOG 0-1, 79% prior chemo (median 1 line), 40% prior RT to a different area. Median baseline BPI 4.8.
4Gy total, delivered as 2Gy x 2 or 4Gy x 1 (29% received 4Gy x 1). Reirradiation with a clinician-choice regimen could be considered at 4 weeks after initial treatment for inadequately controlled pain (the inequality symbol is garbled in the source). Target volume and technique not stated in source.
Primary: proportion with self-reported pain response at 4 weeks. Response was scored on average BPI and oral morphine equivalent dosing per the International Consensus on Palliative RT, assessed at 4 weeks, 8 weeks and 6 months.
Response rates by timepoint are in the table. Median BPI and OMED decreases were 2.25 and 5mg at 4 weeks and 2.75 and 6.2mg at 8 weeks. Median time to pain relief was 36 days, median duration 148 days, with no difference by fractionation.
| Timepoint | ITT CR+PR | Per protocol CR+PR | Did not complete |
|---|---|---|---|
| 4 wks | 40/70 (57%) | 40/68 (59%) | 2/70 (2%) |
| 8 wks | 33/70 (47%) | 33/52 (63%) | 18/70 (26%) |
| 6 mo | 37/70 (53%) | 37/45 (82%) | 25/70 (36%) |
No grade 3+ treatment-related toxicity. Lower-grade events and hematologic toxicity are not reported in the source, although marrow sparing was the stated rationale.
The source states there is no consensus on the most effective palliative dose in MM. The ultralow-dose concept comes from indolent lymphoma, where FoRT tested it against a conventional dose. With no comparator arm here, the 59% at 4 weeks cannot be ranked against conventional palliative fractionation.
Missing assessments grow from 2/70 at 4 weeks to 25/70 at 6 months, and reasons are not given, so the late per-protocol rates are vulnerable to informative dropout. Handling of reirradiated lesions in the 6 month response is not stated. Pain response is self-reported in an unblinded single-arm design.
Best read as a strategy: 4Gy first, escalate on failure. A 63% response at 4 weeks after reirradiation suggests the low first dose did not obviously compromise salvage, at the cost of time (median 95 days to relief after reRT). It does not settle whether 4Gy matches conventional dosing up front, or whether it spares marrow.
Single-arm phase II, 63 pts, no comparator against conventional palliative fractionation; late responses rest on a per-protocol denominator with 36% non-completion at 6 mo.
- 4Gy vs conventional palliative fractionation in MM bone lesions: randomised comparison needed
- Does 4Gy reduce hematologic toxicity vs higher-dose palliative RT?
- Which lesions fail 4Gy and need reirradiation?
📚 Sources · 📄 1 paper
Abstract
The longer read
The premise is marrow sparing. Myeloma is a marrow disease treated with serial myelosuppressive lines, and the abstract cites data that a bone marrow dose of 10 Gy causes hematologic toxicity, so a palliative dose well under that level has a rationale that does not exist for most solid-tumor bone metastases. The concept is borrowed from indolent lymphoma, where FoRT tested ultralow-dose RT against a conventional dose, and from the general radiosensitivity of plasma cell disease. What the abstract does not deliver is the marrow endpoint itself: the only safety statement is the absence of grade 3+ treatment-related toxicity, with no blood count data, so the hypothesis that motivated the dose is asserted and not shown.
The efficacy read depends on which denominator you accept. Per protocol, response climbs from 59% at 4 weeks to 63% at 8 weeks and 82% at 6 months, and the authors conclude that the proportion with improved pain increased over time. By intention to treat, the same lesions give 40/70 (57%), 33/70 (47%) and 37/70 (53%), because 18/70 (26%) and then 25/70 (36%) did not complete the later assessments. An apparent rise built on a shrinking denominator is the usual signature of informative dropout: pts whose pain is controlled keep returning questionnaires, and those who progressed, were reirradiated, or deteriorated may not. The abstract does not say why assessments were missed, so the 82% is better treated as a ceiling and the 53% as a floor.
Two further details complicate the durability claim. The median time to pain relief was 36 days, which falls after the 4-week primary assessment, so the primary endpoint may undercount eventual responders while also telling you relief is slow for a symptomatic pt. And 24% received a second course, at a median dose of 20Gy and a median of 71 days after the 4Gy treatment. The abstract does not state whether a lesion that responded only after reirradiation counts as a responder at 6 months. If it does, part of the late response belongs to the higher-dose second course and not to 4Gy.
The fairest framing is a strategy trial: 4Gy first, escalate on failure. Read that way, the relevant facts are that the first step worked at 4 weeks in 40/70 lesions by ITT and that reirradiation produced a 63% response at 4 weeks, which suggests the low first dose did not obviously compromise salvage. The cost is time: median time to relief after reirradiation was 95 days. Without a randomised arm there is no way to know how many nonresponders would have responded up front to a conventional regimen, and that is the comparison a radiation oncologist needs before changing a default.
Population matters for transfer. This was a favorable group: 89% ECOG 0-1, a median of 1 prior line, uncomplicated lesions only, median baseline BPI 4.8. Nothing here speaks to complicated lesions, where structural or neurologic risk and not analgesia alone drives the dose. Accrual ran from 4/2019 to 9/2025 across 7 institutions to reach 63 evaluable pts, a pace that hints at selective enrollment. The result justifies a randomised comparison with marrow and pain endpoints; on its own it supports the approach as an option in selected pts, not as a replacement for standard palliative dosing.